A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Nemvaleukin-alfa (Primary) ; Nemvaleukin-alfa (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Registrational; Therapeutic Use
- Acronyms ARTISTRY-6
- Sponsors Alkermes; Mural Oncology
- 27 Jun 2024 Planned number of patients changed from 176 to 180.
- 27 Jun 2024 Planned End Date changed from 1 Sep 2025 to 1 Sep 2026.
- 27 Jun 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Jun 2025.